Skip to main content
Top
Published in: Quality of Life Research 5/2009

01-06-2009

How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses

Authors: Peter M. Fayers, Madeleine T. King

Published in: Quality of Life Research | Issue 5/2009

Login to get access

Excerpt

In 1988 the Lancet published a very large randomised clinical trial of intravenous streptokinase, oral aspirin, both, or neither for treatment of suspected acute myocardial infarction [1]. The ISIS-2 trial recruited 17,187 patients from 417 hospitals. The authors concluded that there were benefits both from streptokinase and from aspirin. This paper contained a complex table reporting subgroup analyses, and rather intriguingly, the first analysis was by astrological birth sign. The results suggested that for people born under the star signs Gemini and Libra, aspirin was no better than placebo; for others, aspirin had a strongly beneficial effect. Why, one might wonder, did a highly respected journal publish such arrant nonsense? …
Appendix
Available only for authorised users
Literature
1.
go back to reference ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii, 349–360. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii, 349–360.
2.
go back to reference Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni method. British Medical Journal, 310, 170.PubMed Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni method. British Medical Journal, 310, 170.PubMed
6.
go back to reference Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology, 57, 229–236. doi:10.1016/j.jclinepi.2003.08.009.PubMedCrossRef Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology, 57, 229–236. doi:10.​1016/​j.​jclinepi.​2003.​08.​009.PubMedCrossRef
9.
go back to reference Yusuf, S., Wittes, J., Probstfield, J., & Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of the American Medical Association, 266, 93–98. doi:10.1001/jama.266.1.93.PubMedCrossRef Yusuf, S., Wittes, J., Probstfield, J., & Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of the American Medical Association, 266, 93–98. doi:10.​1001/​jama.​266.​1.​93.PubMedCrossRef
10.
go back to reference Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5(33), 1–56. From http://www.hta.nhs.uk/fullmono/mon533.pdf. Accessed 12 March 2009. Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5(33), 1–56. From http://​www.​hta.​nhs.​uk/​fullmono/​mon533.​pdf. Accessed 12 March 2009.
11.
12.
go back to reference Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). Statistics in medicine—reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357, 2189–2194. doi:10.1056/NEJMsr077003.PubMedCrossRef Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). Statistics in medicine—reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357, 2189–2194. doi:10.​1056/​NEJMsr077003.PubMedCrossRef
13.
go back to reference Martin, V., Cady, R., Mauskop, A., Seidman, L. S., Rodgers, A., Hustard, C. M., et al. (2008). Efficacy of rizatriptan for menstrual migraine in an early intervention model: A prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache, 48, 226–235.PubMedCrossRef Martin, V., Cady, R., Mauskop, A., Seidman, L. S., Rodgers, A., Hustard, C. M., et al. (2008). Efficacy of rizatriptan for menstrual migraine in an early intervention model: A prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache, 48, 226–235.PubMedCrossRef
Metadata
Title
How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses
Authors
Peter M. Fayers
Madeleine T. King
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
Quality of Life Research / Issue 5/2009
Print ISSN: 0962-9343
Electronic ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-009-9473-3

Other articles of this Issue 5/2009

Quality of Life Research 5/2009 Go to the issue